​

Xenon Pharmaceuticals (XENE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

XENE Stock Forecast

Xenon Pharmaceuticals (XENE) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $50.63, with a high of $60.00 and a low of $42.00. This represents a 24.21% increase from the last price of $40.76.

$35 $40 $45 $50 $55 $60 High: $60 Avg: $50.63 Low: $42 Last Closed Price: $40.76

XENE Stock Rating

Xenon Pharmaceuticals stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 20 Strong Sell Sell Hold Buy Strong Buy

XENE Price Target Upside V Benchmarks

TypeNameUpside
StockXenon Pharmaceuticals24.21%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$42.00
Last Closing Price$40.76$40.76$40.76
Upside/Downside--3.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25415---19
Sep, 25415---19
Aug, 25514---19
Jul, 25514---19
Jun, 25514---19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 28, 2025Wedbush$42.00$37.0213.45%3.04%
Oct 10, 2024Danielle BrillRaymond James$50.00$39.4226.84%22.67%
Oct 01, 2024Douglas TsaoH.C. Wainwright$53.00$39.3734.62%30.03%
Aug 09, 2024Laura ChicoWedbush$49.00$41.0519.37%20.22%
Jun 18, 2024Brian AbrahamsRBC Capital$55.00$36.2551.72%34.94%
Dec 14, 2022Goldman Sachs$60.00$39.5751.63%47.20%
Nov 28, 2022Wells Fargo$50.00$35.8639.43%22.67%
Nov 11, 2022Guggenheim$49.00$35.0040.00%20.22%
Oct 18, 2022Danielle BrillRaymond James$52.00$35.5246.40%27.58%
Aug 11, 2022Leerink Partners$46.00$39.6815.93%12.86%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 13, 2025RBC CapitalOutperformOutperformhold
May 13, 2025Wells FargoOverweightOverweighthold
Feb 28, 2025RBC CapitalOutperformOutperformhold
Oct 01, 2024H.C. WainwrightBuyinitialise
Aug 09, 2024WedbushOutperformOutperformhold
Jun 18, 2024RBC CapitalOutperformOutperformhold
Nov 28, 2023RBC CapitalOutperformOutperformhold
Apr 25, 2023Cantor FitzgeraldOverweightinitialise
Dec 14, 2022Goldman SachsBuyinitialise
Dec 12, 2022Cowen & Co.Outperforminitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.83$-1.81$-2.07$-2.73$-3.01----
Avg Forecast$-0.87$-1.66$-2.09$-2.83$-3.10$-3.73$-4.10$-3.13$-0.08
High Forecast$-0.87$-1.66$-2.09$-2.64$-2.97$-2.41$-2.88$-2.07$-0.08
Low Forecast$-0.87$-1.66$-2.09$-2.91$-3.42$-4.32$-4.82$-4.60$-0.08
Surprise %-4.60%9.04%-0.96%-3.53%-2.90%----

Revenue Forecast

$0 $110M $220M $330M $440M $550M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$32.17M$18.44M$9.43M------
Avg Forecast$30.22M$20.72M$12.16M$2.20M$333.33K$5.67M$37.09M$198.24M$518.49M
High Forecast$30.22M$20.72M$12.16M$2.20M$333.33K$5.67M$37.09M$204.65M$518.49M
Low Forecast$30.22M$20.72M$12.16M$2.20M$333.33K$5.67M$37.09M$191.83M$518.49M
Surprise %6.45%-11.02%-22.42%------

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-28.84M$-78.88M$-125.37M$-182.39M$-234.33M----
Avg Forecast$-58.29M$-110.90M$-139.53M$-182.39M$-213.39M$-224.96M$-257.77M$-289.03M$-5.09M
High Forecast$-58.29M$-110.90M$-139.53M$-176.35M$-198.99M$-161.12M$-192.93M$-138.57M$-5.09M
Low Forecast$-58.29M$-110.90M$-139.53M$-194.45M$-228.83M$-288.81M$-322.62M$-307.51M$-5.09M
Surprise %-50.53%-28.87%-10.14%-9.81%----

XENE Forecast FAQ

Is Xenon Pharmaceuticals stock a buy?

Xenon Pharmaceuticals stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Xenon Pharmaceuticals is a favorable investment for most analysts.

What is Xenon Pharmaceuticals's price target?

Xenon Pharmaceuticals's price target, set by 20 Wall Street analysts, averages $50.63 over the next 12 months. The price target range spans from $42 at the low end to $60 at the high end, suggesting a potential 24.21% change from the previous closing price of $40.76.

How does Xenon Pharmaceuticals stock forecast compare to its benchmarks?

Xenon Pharmaceuticals's stock forecast shows a 24.21% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Xenon Pharmaceuticals over the past three months?

  • October 2025: 21.05% Strong Buy, 78.95% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 21.05% Strong Buy, 78.95% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 26.32% Strong Buy, 73.68% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Xenon Pharmaceuticals’s EPS forecast?

Xenon Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.73, marking a 23.92% increase from the reported $-3.01 in 2024. Estimates for the following years are $-4.1 in 2026, $-3.13 in 2027, and $-0.08 in 2028.

What is Xenon Pharmaceuticals’s revenue forecast?

Xenon Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $5.67M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $37.09M, followed by $198.24M for 2027, and $518.49M for 2028.

What is Xenon Pharmaceuticals’s net income forecast?

Xenon Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-225M, representing a -4.00% decrease from the reported $-234M in 2024. Projections indicate $-258M in 2026, $-289M in 2027, and $-5.092M in 2028.